参考文献/References:
[1]李开林.抗病毒治疗对乙肝相关晚期肝病患者疗效的观察[J].医药前沿,2016,6(26):127-128.
[2]郑建铭,黄翀,鱼康康,等.慢性乙型病毒性肝炎慢加急性肝衰竭患者拉米夫定与恩替卡韦抗病毒治疗的短期病死率比较[J].中国感染与化疗杂志,2018,18(2):132-136.
[3]蒋珊珊.乙肝相关性慢性肝病患者肠道菌群的比较及核苷类抗病毒药物对其的影响[D].广西医科大学,2016.
[4]金彩婷,郭利伟,梁伟峰等.慢性乙型病毒性肝炎肝纤维化无创性血清诊断指标研究进展[J].中华实验和临床感染病杂志(电子版),2018,12(1):11-14.
[5]陈词.丁岗强:乙肝患者抗病毒治疗停药问题[J].肝博士,2017(5):14-15.
[6]张菁,崔剑巍,成伟忠,等.基于"伏邪"说的肝复安治疗慢性乙型病毒性肝炎患者铁代谢异常临床观察[J].上海中医药杂志,2016(8):38-42.
[7]潘佳,江南.慢性乙型病毒性肝炎抗病毒治疗及疗效预测因素的研究进展[J].实用医院临床杂志,2016,13(2):147-151.
[8]刘粟,张锐,邱勇,等.慢性乙型病毒性肝炎患者抗病毒治疗依从性及影响因素的分析[J].湖北民族学院学报(医学版),2017,34(1):44-46.
相似文献/References:
[1]邬 剑,李慧玲.ELISA法和胶体金试纸条法在乙肝表面抗原
检测中的应用研究[J].医学信息,2018,31(09):155.[doi:10.3969/j.issn.1006-1959.2018.09.050]
WU Jian,LI Hui-ling.Application of ELISA and Colloidal Gold Strip in the Detection of Hepatitis B Surface Antigen[J].Journal of Medical Information,2018,31(07):155.[doi:10.3969/j.issn.1006-1959.2018.09.050]
[2]张 赓.自身抗体在自身免疫性肝炎和乙型病毒性肝炎中的特征分析[J].医学信息,2020,33(05):173.[doi:10.3969/j.issn.1006-1959.2020.05.059]
ZHANG Geng.Analysis of the Characteristics of Autoantibodies in Autoimmune Hepatitis and Viral Hepatitis B[J].Journal of Medical Information,2020,33(07):173.[doi:10.3969/j.issn.1006-1959.2020.05.059]
[3]王露露.2019-2021年锦州乙型病毒性肝炎的流行病学特征[J].医学信息,2021,34(24):128.[doi:10.3969/j.issn.1006-1959.2021.24.032]
WANG Lu-lu.Epidemiological Characteristics of Viral Hepatitis B in Jinzhou from 2019 to 2021[J].Journal of Medical Information,2021,34(07):128.[doi:10.3969/j.issn.1006-1959.2021.24.032]
[4]宋 丹,韩亚凤.2010~2019年天津市河北区乙型病毒性肝炎流行病学分析[J].医学信息,2020,33(16):125.[doi:10.3969/j.issn.1006-1959.2020.16.039]
SONG Dan,HAN Ya-feng.Epidemiological Analysis of Viral Hepatitis B in Hebei District of Tianjin from 2010 to 2019[J].Journal of Medical Information,2020,33(07):125.[doi:10.3969/j.issn.1006-1959.2020.16.039]
[5]刘 芳,季 良,姜海燕,等.肝爽颗粒联合富马酸替诺福韦二吡呋酯片对乙型病毒性肝炎肝硬化患者APRI、FIB-4的影响[J].医学信息,2021,34(05):104.[doi:10.3969/j.issn.1006-1959.2021.05.029]
LIU Fang,JI Liang,JIANG Hai-yan,et al.The Effect of Ganshuang Granule Combined with Tenofovir Disoproxil Fumarate Tablets on APRI and FIB-4 in Patients with Hepatitis B Liver Cirrhosis[J].Journal of Medical Information,2021,34(07):104.[doi:10.3969/j.issn.1006-1959.2021.05.029]
[6]成若晨,张 璎,何腾飞,等.原卟啉Ⅸ在HBV相关肝硬化中的临床意义[J].医学信息,2021,34(06):73.[doi:10.3969/j.issn.1006-1959.2021.06.019]
CHENG Ruo-chen,ZHANG Ying,HE Teng-fei,et al.The Clinical Significance of Protoporphyrin Ⅸ in HBV-related Liver Cirrhosis[J].Journal of Medical Information,2021,34(07):73.[doi:10.3969/j.issn.1006-1959.2021.06.019]
[7]谭子跃.干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响[J].医学信息,2023,36(20):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]
TAN Zi-yue.Effect of Interferon Combined with Entecavir in the Treatment of Patients with Hepatitis B and its Effect on Liver Function[J].Journal of Medical Information,2023,36(07):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]